Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News
July 20th 2024

Study Reveals Top Treatment Priorities in Patients With CLL

July 16th 2024

Advancements in CLL: A Conversation With Dr Brian Koffman

July 13th 2024

Study Finds Pirtobrutinib Associated With Improved Outcomes vs Venetoclax in Relapsed CLL

July 10th 2024

Zanubrutinib Safer Than Ibrutinib in Patients With B-Cell Malignancies

July 6th 2024

Report Recommends Strategy to Identify CLL in Patient With Posterior Uveitis

Video Series
View All
July 23rd 2024

Optimizing Therapy Sequencing in CLL

July 23rd 2024

Empowering Patients: Key Considerations for BTK Inhibitor Adherence

July 12th 2024

Factors Influencing Choice of Second-Generation BTKi Monotherapy

July 12th 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

June 28th 2024

CLL Treatment Landscape: Overview of BTK Inhibitors

June 28th 2024

Recent Trends and Innovations in the Management of CLL

Video Interviews
View All
July 23rd 2024

Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL

February 11th 2024

Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma

February 2nd 2024

Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape

August 23rd 2023

Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL

More News

Asian patient | Image Credit: kapinon-stock.adobe.com
July 2nd 2024

VenR Achieves Strong Results in Japanese CLL/SLL Cohort

Jared Kaltwasser
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are rare in Japan, but a new report affirms the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) (VenR) in this population.
leukemia word map | Image Credit: dizain-stock.adobe.com
Published: June 28th 2024 | Updated: June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser
Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.
the word fatigue | Image Credit: andrew-stock.adobe.com
June 22nd 2024

Tired of It: Cancer-Related Fatigue in Lymphoma, CLL

Gayle Turim Dickstein
In the realm of lymphoma and chronic lymphocytic leukemia (CLL), and of the treatments that address them, a global survey of nearly 7000 patients proves there’s a long way to go to eliminate cancer-related fatigue from their lives.
leukemia diagnosis | Image Credit: Vitalii Vodolazskyi-stock.adobe.com
June 19th 2024

Transforming CLL Management With Emerging Prognostic Markers

Kimberly Rath, PharmD
This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and overall survival.
concept of heart issues | Image Creditz; ArtemisDiana-stock.adobe.com
June 15th 2024

Study Finds Genetic Indicators linked to BTK Inhibitor–Related Cardiotoxicity

Kimberly Rath, PharmD
Researchers have found that specific genetic markers may increase the risk of cardiovascular adverse effects in patients using Bruton’s tyrosine kinase (BTK) inhibitors.
Patient and doctor | Image Credit: ©DragonImages - adobe.stock.com
June 12th 2024

Formulary Switch From Ibrutinib to Zanubrutinib Yields Positive Safety, Efficacy Data

Christina Mattina
A real-world report showed the safety and efficacy of zanubrutinib after a community oncology practice replaced ibrutinib with the newer Bruton tyrosine kinase inhibitor on its formulary.
Stethoscope on charts | Image Credit: © amazing studio - stock.adobe.com.jpeg
June 7th 2024

Next-Gen BTKis Show Efficacy, Safety Edge Over Ibrutinib in Real-World Setting

AJMC Contributor
An abstract presented at the 2024 American Society of Clinical Oncology annual meeting showed that patients treated with zanubrutinib or acalabrutinib had more favorable safety and efficacy outcomes.
Medical data | Image Credit: © everythingpossible - stock.adobe.com
June 6th 2024

Real-World Database Yields New Potential Safety Signals for Bendamustine

Jared Kaltwasser
The authors said their analysis should help clinicians better monitor patients for potential adverse events.
CLL on a keyboard | Image Credit: © momius - stock.adobe.com
June 4th 2024

Long-Term Analysis From DUO Trial Affirms Benefits of Duvelisib

Jared Kaltwasser
The new data shed light on long-term outcomes for patients receiving duvelisib, although the investigators said the treatment landscape has also shifted significantly since the original trial.
Blood smear from a cancer patient | Image Credit: Chansom Pantip-stock.adobe.com
May 31st 2024

BET Inhibition Reduces CLL Burden, Boosts Immune Function

Kimberly Rath, PharmD
BET inhibition in chronic lymphocytic leukemia (CLL) significantly reduces leukemic cell burden and restores T-cell function by modulating the immune microenvironment and reversing T-cell exhaustion.
Patient in a hospital bed with doctor | Image credit: Tyler Olson - stock.adobe.com
May 21st 2024

SID Heightens Infection Risk in Patients With B-Cell Malignancies

Jared Kaltwasser
A new report finds secondary immunodeficiency disease (SID) also increases the risk of mortality in patients with B-cell malignancies.
Liver scan by a robot | Image Credit: adisak-stock.adobe.com
May 21st 2024

Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL

Gayle Turim Dickstein
A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Ibrutinib Shows Similar Efficacy Across Trials in Chronic Lymphocytic Leukemia
May 17th 2024

Ibrutinib Shows Similar Efficacy Across Trials in Chronic Lymphocytic Leukemia

Luke Halpern
Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials.
Lymphoma word block image | Image Credit: airdone-stock.adobe.com
May 15th 2024

Important Insights Regarding Primary Breast Lymphoma

Luke Halpern
Due to the rarity of primary breast lymphoma, individualized treatment plans that consider overall health, symptoms, and patient preferences should be curated.
Nurse holding older woman's hands - Cecilie Arcurs/peopleimages.com - stock.adobe.com.jpeg
May 10th 2024

Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure

Gayle Turim Dickstein
The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Image of a doc reviewing a case report | Image Credit: fedrunovan - stock.adobe.com
May 8th 2024

CLL Followed by CML: A Rare Case Described

Gayle Turim Dickstein
A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of targeted kinase inhibitors.
Enhanced image of leukemia | Image Credit: freshidea - stock.adobe.com
May 2nd 2024

Targeted Therapies for CLL Can Lead to Improved Patient Outcomes

Luke Halpern
There was a marked increase in the prevalence of targeted therapy among patients with chronic lymphocytic leukemia (CLL), which corresponded to positive overall survival rates observed in the study.
Keyboard with a blue chronic lymphocytic leukemia key | Image credit: momius - stock.adobe.com
April 28th 2024

Targeted Combinations, Cellular Therapies, and Bispecific Antibodies Forge a New Path in CLL Management

Kimberly Rath, PharmD
An overview of the treatments for chronic lymphocytic leukemia (CLL) and novel therapies on the horizon, including double and triple combination therapies, cellular therapies, and bispecific antibodies.
CLL on a keyboard | Image Credit: momius - stock.adobe.com
April 26th 2024

Research Unveils UGT2B17 as Key Prognostic Marker in CLL

Kimberly Rath, PharmD
UGT2B17, a metabolic enzyme known for regulating various endogenous molecules, has been identified to have heightened expression in the B cells of patients who have chronic lymphocytic leukemia (CLL).
CLL cells in blood flow - Laszlo-stock.adobe.com
April 24th 2024

Long-Term, Real-World Data Support Ibrutinib Efficacy, Safety in CLL

Gayle Turim Dickstein
EVIdeNCE study data, from real-world practice, confirm the efficacy and safety that ibrutinib previously demonstrated in clinical trials involving patients with CLL, according to the study authors.
Leukemia word bubble | Image Credit: chrupka - stock.adobe.com
April 17th 2024

Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study

Kimberly Rath, PharmD
Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Older woman fatigue headache depression | Image Credit: © fizkes - stock.adobe.com
April 12th 2024

Nonpharmacological Approaches Lead to Significant Alleviation of CLL-Associated Fatigue

Jared Kaltwasser
Investigators said both reflexology and acupressure led to similar improvement in patients after 4 weeks.
White blood cells from leukemia | Image Credit: SebastianKaulitzki - stock.adobe.com
April 9th 2024

Venetoclax Monotherapy Leads to Durable Responses in Relapsed, Refractory CLL

Jared Kaltwasser
The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.
Broken arm in cast | Image credit: Thinapob - stock.adobe.com
April 5th 2024

Several Factors—but Not Osteoporosis—Increase Risk of Fractures in People With CLL

Jared Kaltwasser
Most fragility fractures experienced by people with chronic lymphocytic leukemia (CLL) are vertebral, the study found.
Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL
April 3rd 2024

Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL

Jared Kaltwasser
Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.
Gene mutation | Image Credit: © Ilya-stock.adobe.com.jpeg
March 30th 2024

Review Chronicles Advancing Insights Into Epigenetic Alterations in Chronic Lymphocytic Leukemia

Luke Halpern
Studies of DNA methylation, RNA methylation, and histone modification revealed important information about the pathology of chronic lymphocytic leukemia and treatment potential.
Lymphoma graphic| Image Credit: MP Studio - stock.adobe.com
March 27th 2024

Study Supports Use of EORTC Item Library to Assess Lymphoma Symptoms

Luke Halpern
Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.
Abstract concept of scientific research | Image Credit: kras99 - stock.adobe.com
March 23rd 2024

Review Outlines Management of Patients Receiving Venetoclax for CLL

Jared Kaltwasser
Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.
Chronic lymphocytic leukemia | Image Credit: momius - stock.adobe.com
March 20th 2024

Quest to Advance CLL Therapy Operating on Multiple Fronts

Jared Kaltwasser
There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.
Bioinformatics and Health Informatics Concept Medical and Informatics Icons on Technology Background | Image credit: ArtemisDiana - stock.adobe.com
March 16th 2024

Genomics, Transcriptomics, and Epigenomics Utilized to Better Understand Chemoimmunotherapy Resistance in CLL

Luke Halpern
Advances in multi-omics have led to large scale studies that can provide a better prediction method for adequate therapy choices in patients with chronic lymphocytic leukemia (CLL).
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo